Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease

Jonas S. Heitmann, MD, Daniela Dörfel, MD, Sabine Kayser, MD, Michael Heuser, Felicitas Thol, Silke Kapp-Schwoerer, MD, Wolfgang Bethge, MD, Ludger Grosse-Hovest, Martin Steiner, Melanie Märklin, PhD, Juliane S. Walz, MD, Richard F. Schlenk, Gundram Jung, MD, Helmut R. Salih

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-139493

Published: 2020

Journal Articles

Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

Sabine Kayser, MD, Jonas S. Heitmann, MD, Daniela Dörfel, MD, Felicitas Thol, MD, Michael Heuser, MD, Melanie Märklin, PhD, Carsten Müller-Tidow, MD, Martin Steiner, Ludger Grosse-Hovest, Gundram Jung, MD, Richard F. Schlenk, MD, Helmut R. Salih, MD

Blood (2019) 134 (Supplement_1): 3928.

https://doi.org/10.1182/blood-2019-125327

Published: 2019

Journal Articles

Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion

Blood (2018) 132 (Supplement 1): 769.

https://doi.org/10.1182/blood-2018-99-118047

Published: 2018

Journal Articles

Involvement of NFAT Transcription Factors in NK Cell Reactivity

Kathrin Rothfelder, MSc, Melanie Märklin, PhD, Julia Wild, MSc, Daniela Dörfel, MD, Lothar Kanz, MD, Martin R Müller, MD PhD, Helmut R. Salih, MD

Blood (2016) 128 (22): 1344.

https://doi.org/10.1182/blood.V128.22.1344.1344

Published: 2016

Journal Articles

The TLR7/8 Ligand R848 Is Superior In Generation of Monocyte Derived Dendritic Cells From AML Patients for the Induction of Potent T and NK Cell Immune Responses

Daniela Dorfel, MD, Barbara Beck, PhD, Christiane Geiger, PhD, Felix Lichtenegger, MD, Lysann Lindner, Martina Merk, Dolores Schendel, PhD, Marion Subklewe, MD

Blood (2010) 116 (21): 2195.

https://doi.org/10.1182/blood.V116.21.2195.2195

Published: 2010

NARROW

First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease

Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion

Involvement of NFAT Transcription Factors in NK Cell Reactivity

The TLR7/8 Ligand R848 Is Superior In Generation of Monocyte Derived Dendritic Cells From AML Patients for the Induction of Potent T and NK Cell Immune Responses

Email alerts

ASH Publications

American Society of Hematology

First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease

Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion

Involvement of NFAT Transcription Factors in NK Cell Reactivity

The TLR7/8 Ligand R848 Is Superior In Generation of Monocyte Derived Dendritic Cells From AML Patients for the Induction of Potent T and NK Cell Immune Responses

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only